Sounds like a legit retirement. And a loss of a director shouldn't be a major hit.
Management isn't crashing the market. Take a look at the bio ETF's IBB and XBI, losing some major ground. Though even before this SESN has been taking quite the hit. Need something to get this back over the $.
Dr. Dixon has a 36 year career in the Pharma and Biotech business, combining a technical background and experience in drug development and regulatory affairs with commercial responsibilities in building and leading organizations and launching and growing more than 20 major global pharmaceutical products. She is on the Board of Directors for a number of Public BioPharma companies (Alkermes Plc, Incyte Corporation, bluebird bio and Eleven Biotherapeutics) and was formerly on the Board of Ardea Biosciences (sold to AZ in 2012), Furiex (sold to Forest in 2014), Orexigen Therapeutics and Dentsply International. She is a member of NACD and has experience on Governance and Nominating, Audit, and Compensation Committees as well as special Commercial and R&D Board Committees.
She also is the Principal of Great Meadow Consulting that has helped small and large BioPharma companies with strategic planning, product development/commercialization planning, organizational design and talent mentoring. She has also served as an expert witness.
News 
Market Data 
Discover 
